Sponsored Links 
Regenerate with Regeneron
Regeneron Pharmaceuticals, Inc. (REGN - Analyst Report) is a biopharmaceutical company engaged in the development and marketing of therapeutic medicines for the treatment of serious medical conditions. Its lead candidates are VEGF-Trap for the treatment of cancers, eye diseases, and IL-1 Trap for CAPS and gout.
The company recently received the FDA approval of Arcalyst for CAPS [CIAS1-Associated Periodic Syndrome, a rare genetic disorder]. It also has a number of pre-clinical drug candidates for other disorders.
The company made impressive progress in recent months in terms of clinical advances and business developments. We maintain our Buy rating on its shares with a price target of $28.
Read the full analyst report on REGN
 |
 |
 Share |
 RSS |
 Rate Pos |
 Rate Neg |
 Comment |
|
|
||||||
Loading Stories...Related Content
Loading Stories...Most Popular on Zacks.com
1.49 %
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
More Zacks Links
| Market Summary | Nov 08, 2009 12:52 pm ET |
Sponsored Links
[CLICK TO CLOSE X]